Clinical Trial Update: A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) [Phase 2]

View source ↗

Summary

A phase 2 study of ridaforolimus in KRAS-mutant non-small cell lung cancer sponsored by Merck Sharp & Dohme was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED